Rejection
15
3
3
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.7%
1 terminated out of 15 trials
87.5%
+1.0% vs benchmark
13%
2 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation
The Role of the Opioid System in Placebo Effects on Pain and Social Rejection
TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation
Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients
Monitoring Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood Lymphocytes of Kidney Transplant Recipients
Study of Glycemic Control on Liver Transplantation Outcomes
Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
Medication Adherence Enhancement in Heart Transplant Recipients
Long-Term Study On Home Spirometry After Lung Transplantation
Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients